Mainz teams up with Labor Staber to market colorectal cancer test ColoAlert in Germany
fotostorm
- Mainz Biomed (NASDAQ:MYNZ) is collaborating with Dr Staber & Kollegen (Labor Staber) to expand commercialization of its at-home colorectal cancer (CRC) screening test ColoAlert in Germany.
- Mainz said Labor Staber has more than 800 employees and offers medical diagnostics and services from a single source. Labor Staber provides doctors and hospitals with medical laboratory services at nine locations in Germany.
- "We continue to build mutually beneficial partnerships with diagnostic labs such as Labor Staber, as we have found putting our PCR testing kits in the hands of highly professional laboratory networks to be a much more effective business model than the traditional methodology of operating testing at a single facility," said Mainz CEO Guido Baechler.
- MYNZ +2.64% to $6.60 premarket March 15